Ibrutinib plus venetoclax demonstrated superior PFS and a higher complete response rate compared with ibrutinib plus placebo in patients with relapsed or refractory mantle cell lymphoma, according ...

The FDA reviews an all-oral treatment for newly diagnosed AML, combining decitabine, cedazuridine, and venetoclax, showing ...

A panelist discusses how ASCO 2025's most important breakthrough was the oral decitabine plus venetoclax combination, ...

A study reveals that venetoclax consolidation after BTKi therapy is effective for chronic lymphocytic leukemia, offering promising outcomes for patients.

Switching to venetoclax led to sustained high rates of undetectable minimal residual disease, the investigators found.

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 2 study titled ‘A ...

While venetoclax plus obinutuzumab received FDA approval in 2019 for less-fit CLL patients based on results of the CLL14 trial (showing superiority versus chlorambucil-obinutuzumab), ...

The addition of venetoclax to azacitidine benefited untreated patients with isocitrate dehydrogenase mutations ineligible for intensive chemotherapy, according to study results presented at the ...

Adding the targeted therapy venetoclax (Venclexta, AbbVie) to high-dose chemotherapy is a "step forward" for pediatric patients with relapsed or refractory acute myeloid leukemia (AML), says an ...

The US Food and Drug Administration (FDA) has issued a partial hold on all ongoing clinical trials of venetoclax (Venclexta/Venclyxto, AbbVie) in the treatment of multiple myeloma, owing to an ...